Veracyte (NASDAQ:VCYT – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, risk, valuation, dividends, institutional ownership, profitability and analyst recommendations.
Institutional & Insider Ownership
58.7% of Connect Biopharma shares are owned by institutional investors. 1.6% of Veracyte shares are owned by insiders. Comparatively, 22.6% of Connect Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings and target prices for Veracyte and Connect Biopharma, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Veracyte | 1 | 2 | 6 | 2 | 2.82 |
| Connect Biopharma | 1 | 0 | 7 | 0 | 2.75 |
Earnings & Valuation
This table compares Veracyte and Connect Biopharma”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Veracyte | $517.15 million | 6.81 | $66.35 million | $1.41 | 31.08 |
| Connect Biopharma | $60,000.00 | 1,122.97 | -$55.48 million | ($1.19) | -0.90 |
Veracyte has higher revenue and earnings than Connect Biopharma. Connect Biopharma is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Veracyte has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.23, indicating that its share price is 123% less volatile than the S&P 500.
Profitability
This table compares Veracyte and Connect Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Veracyte | 20.37% | 9.26% | 8.61% |
| Connect Biopharma | N/A | -165.41% | -121.58% |
Summary
Veracyte beats Connect Biopharma on 10 of the 15 factors compared between the two stocks.
About Veracyte
Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm’s portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.
About Connect Biopharma
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.
